Anti-Obesity Drugs Market Growth

Development of Novel Compounds to Drive Anti-obesity Drugs Market Growth; Market Size to Reach USD 106.5 billion by 2035 | Roots Analysis

 

According to a recently published report by Roots Analysis, the rising global prevalence of obesity and increased awareness of its associated health risks coupled with the growing demand for safe and effective weight loss drugs is driving the anti-obesity drugs market growth

Anti-obesity Drugs Industry Overview

The global anti-obesity drugs market size is estimated to reach over USD 106.5 billion by 2035, growing at a CAGR of 10.0% in the forecast period, till 2035.

Anti-obesity drugs, also known as weight loss drugs, include a range of pharmaceutical treatments designed to assist individuals in managing obesity and associated concerns, such as diabetes mellitus and cardiovascular disorders. These medications promote weight loss by influencing appetite regulation, fat absorption and metabolism. It is worth mentioning that in the recent years, several new anti-obesity drugs have received regulatory approval, expanding the options available to patients, offering alternatives to bariatric surgery. Additionally, the ongoing advancements in drug formulation and delivery systems, coupled with the development of novel compounds, have led to the emergence of more effective and safer anti-obesity medications.

Notably, the rise in telehealth services and digital therapeutics is further facilitating better patient engagement and adherence to the treatment regimen. Consequently, the aforementioned factors are likely to present lucrative market growth opportunities for drug developers and this domain is anticipated to experience enormous growth in the coming years.

Browse 100+ figures and 110+ market data tables spread across ~230 slides and detailed Table of Content on “Anti-obesity Drugs Market by Type of Molecule (Biologics and Small Molecules), Active Compound Used (Tirzepatide, Semaglutide, Retatrutide, Survodutide, Cagrilintide and Semaglutide, Orforglipron, Liraglutide and Other Active Compounds), Mechanism of Action (GLP-1 Agonist / GIP Agonist, GLP-1 Agonist / GCGR Agonist, GLP-1 Agonist, GLP-1 Agonist / Amylin Analogue, GLP-1 / GCGR / GIP Agonist and Other Mechanisms of Action), Type of Agonist (Single-Agonist, Dual-Agonist and Tri-Agonist), Action Pathway (Centrally Acting, Peripherally Acting and Centrally Acting and Peripherally Acting), Route of Administration (Oral and Parenteral), Geographical Regions (North America, Europe, Asia-Pacific and Latin America), Sales Forecast and Leading Drug Developers” here:
https://www.rootsanalysis.com/reports/anti-obesity-drugs-market.html

Market Drivers

Several factors are propelling the anti-obesity drugs market growth. A report from the World Obesity Atlas predicts that by 2035, over half of the global population will be categorized as obese. This rise in the prevalence of obesity has led to a significant increase in the demand for effective pharmaceutical solutions. Additionally, rising public awareness of the health risks associated with obesity has spurred advancements in the anti-obesity domain. This has encouraged the pharmaceutical companies to invest more in research and development of anti-obesity drugs. These factors collectively contribute to the growth of anti-obesity drugs within the pharmaceutical industry.

Market Restraints

While the anti-obesity drugs market is experiencing substantial growth, there are certain restraints that can hinder the growth of the industry. One of the primary factors include the relatively high cost of anti-obesity medications which limits their accessibility to patients in low and middle-income countries. In addition, most of the clinical trials for these drugs are relatively short-term (lasting for 1-2 years), leading to disparity on the long-term maintenance of weight loss through these drugs. In addition, the adverse effects associated with these drugs, including nausea, vomiting and diarrhea can adversely impact the patient experience and present significant hurdles during the drug approval processes. Consequently, all these factors may pose a significant challenge for the anti-obesity drug developers.

Growth Factors

Despite the aforementioned challenges, various growth factors continue to drive the anti-obesity drugs market forward. One of the primary factors include the ongoing clinical advancements in the domain; researchers and drug developers are focusing on developing drugs that employ innovative mechanisms with an emphasis on improving metabolic health and achieving effective weight loss. Moreover, the integration of digital health technologies, such as mobile health applications and smart wearables, presents a significant opportunity for the management of obesity, which is likely to revolutionize the field of personalized medications and enhance treatment efficacy and patient compliance.

Anti-obesity Drugs Market Segments

Based on the type of molecule, the market is segmented into biologics and small molecules

• The small molecules segment is likely to capture the largest revenue share of around 55% in the anti-obesity drugs market in 2024.
• The biologics segment is anticipated to be the fastest growing segment in this industry, with an annualized growth rate (CAGR) of 23.8%, during the forecast period.

Based on the active compound used, the market is segmented into tirzepatide, semaglutide, retatrutide, survodutide, cagrilintide and semaglutide, orforglipron, liraglutide, other active compounds

• The semaglutide segment is likely to capture the largest revenue share of around 55% in the anti-obesity drugs market in 2024.
• The tirzepatide segment is anticipated to be the fastest growing segment in this industry, with an annualized growth rate (CAGR) of 21.1%, during the forecast period.

Based on the mechanism of action, the market is segmented into GLP-1 agonists / GIP agonists, GLP-1 agonists / GCGR agonists, GLP-1 agonists, GLP-1 agonists / Amylin analogues, GLP-1 / GCGR / GIP agonists and other mechanisms of action

• The GLP-1 agonists segment is likely to capture the largest revenue share of 65% in the anti-obesity drugs market in 2024.
• The GLP-1 agonists / GIP agonists segment is anticipated to be the fastest growing segment in this industry, with an annualized growth rate (CAGR) of 21.1%, during the forecast period.

Based on the type of agonist, the market is segmented into single-agonists, dual-agonists and tri-agonists

• The single-agonists segment is likely to capture the largest revenue share of around 70% in the anti-obesity drugs market in 2024.
• The dual-agonists segment is anticipated to be the fastest growing segment in this industry, with an annualized growth rate (CAGR) of 25.7%, during the forecast period.

Based on the action pathway, the market is segmented into centrally acting, peripherally acting, centrally acting and peripherally acting drugs

• The centrally acting drugs segment is likely to capture the largest revenue share of around 85% in the anti-obesity drugs market in 2024.
• The centrally acting drugs segment is anticipated to be the fastest growing segment in this industry, with an annualized growth rate (CAGR) of 22.6%, during the forecast period.

Based on the route of administration, the market is segmented into oral and parenteral route of administration  

• The segment for parenteral route of administration is likely to capture the largest revenue share of more than 95% in the anti-obesity drugs market in 2024.
• The segment for oral route of administration is anticipated to be the fastest growing segment in this industry, with an annualized growth rate (CAGR) of 40.6%, during the forecast period.

Based on the regional insights, the market is segmented into North America, Europe, Asia-Pacific and Latin America

• North America is likely to dominate the anti-obesity drugs market, by capturing the largest revenue share of nearly 70%, in 2024.
• In Asia-Pacific, the anti-obesity drugs market is likely to demonstrate considerable growth with a relatively higher CAGR (~40%) during the forecast period.

Key Companies Profiled

The anti-obesity drugs market report also includes profiles of key players (listed below in alphabetical order) that are engaged in the anti-obesity domain:

• Adocia
• AstraZeneca
• Boehringer Ingelheim
• CinFina Pharma
• Eli Lilly
• Gmax Biopharma
• Hanmi Pharm
• Jiangsu Hengrui Pharmaceuticals
• Kallyope
• Novo Nordisk
• PegBio
• Pfizer
• QL Biopharm
• Regeneron
• Roche
• Sciwind Biosciences
• Viking Therapeutics
• Zealand Pharma

You Can Download Free Sample PDF Copy of This Report At:
https://www.rootsanalysis.com/reports/anti-obesity-drugs-market.html

About Roots Analysis

Roots Analysis is a global leader in market research, competitive intelligence and consulting services. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

Contact Details

Gaurav Chaudhary

Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com